Solid Biosciences Inc. (SLDB): Price and Financial Metrics


Solid Biosciences Inc. (SLDB): $1.16

0.03 (+2.65%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add SLDB to Watchlist
Sign Up

Industry: Biotech


Ranked

of 455

in industry

SLDB POWR Grades


  • Growth is the dimension where SLDB ranks best; there it ranks ahead of 75.98% of US stocks.
  • SLDB's strongest trending metric is Value; it's been moving up over the last 169 days.
  • SLDB's current lowest rank is in the Stability metric (where it is better than 5.79% of US stocks).

SLDB Stock Summary

  • Revenue growth over the past 12 months for Solid Biosciences Inc comes in at 213.82%, a number that bests 96.5% of the US stocks we're tracking.
  • In terms of volatility of its share price, SLDB is more volatile than 94.01% of stocks we're observing.
  • Solid Biosciences Inc's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -214.56%, greater than the shareholder yield of only 1.45% of stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Solid Biosciences Inc are ACET, FGEN, ATRA, ONCT, and BBIO.
  • SLDB's SEC filings can be seen here. And to visit Solid Biosciences Inc's official web site, go to www.solidbio.com.

SLDB Valuation Summary

  • In comparison to the median Healthcare stock, SLDB's price/earnings ratio is 110.41% lower, now standing at -3.8.
  • SLDB's price/sales ratio has moved NA NA over the prior 44 months.
  • SLDB's EV/EBIT ratio has moved up 12.9 over the prior 44 months.

Below are key valuation metrics over time for SLDB.

Stock Date P/S P/B P/E EV/EBIT
SLDB 2021-08-31 43.1 1.3 -3.8 -1.3
SLDB 2021-08-30 43.0 1.3 -3.8 -1.3
SLDB 2021-08-27 43.6 1.3 -3.9 -1.3
SLDB 2021-08-26 42.3 1.2 -3.8 -1.2
SLDB 2021-08-25 42.2 1.2 -3.7 -1.2
SLDB 2021-08-24 42.5 1.2 -3.8 -1.2

SLDB's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • SLDB has a Quality Grade of C, ranking ahead of 48.77% of graded US stocks.
  • SLDB's asset turnover comes in at 0.043 -- ranking 329th of 682 Pharmaceutical Products stocks.
  • 500 - Internal server error

The table below shows SLDB's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.043 1 -1.880
2021-06-30 0.036 1 -6.662
2021-03-31 0.024 1 -26.655
2020-12-31 0.000 NA -12.889
2020-09-30 0.000 NA -8.496
2020-06-30 0.000 NA -6.389

SLDB Price Target

For more insight on analysts targets of SLDB, see our SLDB price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $10.33 Average Broker Recommendation 1.78 (Moderate Buy)

SLDB Stock Price Chart Interactive Chart >

Price chart for SLDB

SLDB Price/Volume Stats

Current price $1.16 52-week high $11.58
Prev. close $1.13 52-week low $1.10
Day low $1.10 Volume 2,708,805
Day high $1.19 Avg. volume 1,433,842
50-day MA $1.70 Dividend yield N/A
200-day MA $2.82 Market Cap 127.94M

Solid Biosciences Inc. (SLDB) Company Bio


Solid Biosciences, LLC engages in identifying and developing gene therapies for duchenne muscular dystrophy in the United States. Its lead product candidate includes SGT-001, a gene transfer candidate that is in Phase I/II clinical trial to restore functional dystrophin protein expression in patients’ muscles. The company was formerly known as Solid Ventures, LLC and changed its name to Solid Biosciences, LLC in June 2015. Solid Biosciences, LLC was founded in 2013 and is based in Cambridge, Massachusetts.


SLDB Latest News Stream


Event/Time News Detail
Loading, please wait...

SLDB Latest Social Stream


Loading social stream, please wait...

View Full SLDB Social Stream

Latest SLDB News From Around the Web

Below are the latest news stories about Solid Biosciences Inc that investors may wish to consider to help them evaluate SLDB as an investment opportunity.

Solid Biosciences Outlines its Strategic Priorities for 2022 and Announces Corporate Updates

- Continue to advance SGT-001 by dosing additional patients in IGNITE DMD - - Advance next-generation Duchenne gene therapy program (SGT-003) to IND submission; SGT-003 has demonstrated enhanced muscle tropism and microdystrophin expression - - Company enters 2022 with approximately $210 million in cash and investments - - Ian F. Smith, Chair of the Board of Directors, to assume role of Executive Chair - CAMBRIDGE, Mass., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a

Yahoo | January 10, 2022

Solid Biosciences to Present at 40th Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that Ilan Ganot, Chief Executive Officer, President and Co-Founder, will present at the 40th Annual J.P. Morgan Healthcare Conference on Thursday, January 13, 2022 at 9:00 am ET. Following the prepared remarks, Mr. Ganot will be available for Q&A. Institutional investors interested

Yahoo | January 6, 2022

All You Need to Know About Solid Biosciences Inc. (SLDB) Rating Upgrade to Buy

Solid Biosciences Inc. (SLDB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Yahoo | January 5, 2022

Solid Biosciences Reports Inducement Grant to New Senior Vice President, Human Resources

CAMBRIDGE, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced the grant of inducement awards to its newly appointed Senior Vice President, Human Resources, Allison Bogosian. The grant was approved by a majority of the independent directors of the Company on November 18, 2021 as an inducement material to Ms. Bogosian entering into employment wi

Yahoo | January 4, 2022

Brokerages Anticipate Solid Biosciences Inc. (NASDAQ:SLDB) Will Post Quarterly Sales of $3.48 Million

Analysts predict that Solid Biosciences Inc. (NASDAQ:SLDB) will report sales of $3.48 million for the current quarter, according to Zacks. Three analysts have made estimates for Solid Biosciences’ earnings, with the highest sales estimate coming in at $3.50 million and the lowest estimate coming in at $3.43 million. The company is scheduled to issue its […]

Transcript Daily | December 17, 2021

Read More 'SLDB' Stories Here

SLDB Price Returns

1-mo -32.95%
3-mo -42.86%
6-mo -58.42%
1-year -81.79%
3-year -95.19%
5-year N/A
YTD -33.71%
2021 -76.91%
2020 70.34%
2019 -83.40%
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8452 seconds.